ENBREL in the EU is approved for the following indications: Rheumatoid arthritis: ENBREL in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid ...

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., April 30, 2004 – Amgen (N), today announced that Enbrel® (etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth ...

Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...

Phase-III results for Eli Lilly’s experimental moderate-to-severe plaque psoriasis drug Ixekizumab hints at a possible brawl between the Indiana drugmaker and Amgen, if the FDA approves the drug.

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

Amgen’s Enbrel (etanercept), a blockbuster biologic treatment for a number of autoimmune diseases, including rheumatoid arthritis and psoriasis, has been an attractive target for biosimilar makers.

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has endorsed a new indication for the tumor necrosis factor inhibitor etanercept (Enbrel, Pfizer). On June 26, the ...

In November 2000, Immunex (Seattle, WA) initiated a patient enrollment program designed to increase year-end sales of its anti-inflammatory drug Enbrel. Immunex claims the program was implemented ...

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...